Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3 Recurrence 1 Hematologic Neoplasms 1

Interventions

Cyclophosphamide 27 fludarabine 19 Dexamethasone 18 pembrolizumab 12 Rituximab 12 Etoposide 11 venetoclax 10 pomalidomide 9 Gemcitabine 9 Lenalidomide 8 fludarabine phosphate 7 daratumumab 7 Bortezomib 7 glofitamab 6 carfilzomib 6 Vincristine 6 obinutuzumab 5 Temozolomide 5 Prednisone 5 Nivolumab 5 Immunotherapy, Adoptive 5 Doxorubicin 5 Cytarabine 5 Cisplatin 5 Calcium Dobesilate 5 selinexor 4 cemiplimab 4 Carboplatin 4 Azacitidine 4 zanubrutinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Homoharringtonine × 90 days × Clear all

NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡